CapsoVision, Inc. closed its IPO, raising $27.5 million by selling 5.5 million shares at $5 each.
Quiver AI Summary
CapsoVision, Inc. announced the successful closing of its initial public offering (IPO) on July 3, 2025, selling 5.5 million shares of common stock at $5.00 each, raising gross proceeds of $27.5 million before expenses. The shares began trading on the Nasdaq Capital Market under the ticker "CV." The company granted underwriters a 30-day option for an additional 825,000 shares. CapsoVision specializes in advanced imaging and AI technologies for capsule endoscopy solutions, with its flagship product, CapsoCam Plus®, and a upcoming product, CapsoCam Colon, aimed at enhancing gastrointestinal disease diagnosis. The SEC declared the registration statement effective on July 1, 2025, and full details of the offering can be accessed through the provided prospectus.
Potential Positives
- CapsoVision successfully closed its initial public offering, raising $27.5 million, which will provide essential capital for its ongoing operations and product development.
- The shares began trading on the Nasdaq Capital Market, increasing the company's visibility and accessibility to investors.
- The offering allows for the potential sale of an additional 825,000 shares through underwriters, potentially increasing total funds raised.
Potential Negatives
- The initial public offering (IPO) price of $5.00 per share may indicate weaker demand compared to expectations, raising concerns about the company's valuation and market confidence.
- The company is currently in a commercial-stage but still relies heavily on capital raised through the IPO, suggesting potential financial instability or limited operational cash flow.
- Forward-looking statements included in the release indicate significant risks and uncertainties that could impact future business and financial performance, which may deter potential investors.
FAQ
What is CapsoVision's IPO price per share?
CapsoVision's initial public offering price was set at $5.00 per share.
When did CapsoVision begin trading on Nasdaq?
CapsoVision shares began trading on the Nasdaq Capital Market on July 2, 2025.
How many shares were offered in CapsoVision's IPO?
The company offered 5,500,000 shares of common stock in its initial public offering.
What is CapsoVision's flagship product?
CapsoVision's flagship product is the CapsoCam Plus®, a panoramic capsule endoscope for gastrointestinal imaging.
Who managed CapsoVision's IPO?
The Benchmark Company, LLC and Roth Capital Partners acted as joint book-running managers for the offering.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the closing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares began trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “CV.”
CapsoVision has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $27.5 million.
The Benchmark Company, LLC and Roth Capital Partners acted as joint book-running managers for the offering.
A registration statement on Form S-1 relating to the shares was declared effective by the U.S. Securities and Exchange Commission (SEC) on July 1, 2025. The offering was made only by means of a prospectus forming a part of such registration statement. Copies of the final prospectus may be obtained from The Benchmark Company, LLC, 150 East 58th Street, 17th Floor, New York, NY 10155, Attention: Prospectus Department, or by email at [email protected]
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit
www.capsovision.com
.
Forward-Looking Statements
This press release contains or may contain forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expected”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would” or “may” and other words of similar meaning. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, market conditions, and other risks described in the Company’s registration statement on Form S-1 filed with the SEC. Forward-looking statements speak only as of the date of this press release, and CapsoVision undertakes no obligation to update or revise these statements, except as required by law.
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
[email protected]
Kevin Lundquist
Chief Financial Officer, CapsoVision, Inc.
[email protected]
Media Contact
Leslie Strickler and Paul Spicer
Être Communications
[email protected]
| (804) 240-0807
[email protected]
| (804) 503-9231
